Skip to content

Author

N. Kuse

We have 2 of 78 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Sep 2026

The emerging role of PDE4 inhibitors for the treatment of pulmonary fibrosis

ABSTRACT Introduction Nerandomilast, a phosphodiesterase-4B (PDE4B) preferential inhibitor, was approved in 2025 for the treatment of idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). PDE4 enzymes play a central role in regulating intracellular cyclic adenosine monophosphate (cAMP) and are h...

A. Tyker, N. Kuse, B. Pertzov et al. · 0 citations
Open access Aug 2026

Aberrant expression of the PREX2-MAGI2 axis modulates myofibroblast differentiation in pulmonary fibrosis.

It is suggested that MAGI2 acts as a negative regulator of myofibroblast differentiation by stabilizing PTEN, whereas PREX2 is aberrantly expressed in the fibrotic milieu, negatively modulating MAGI2, thereby accelerating pulmonary fibrosis.

Yozo Sato, K. Kamio, Yasuhiro Terasaki et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.